Exoxemis Exoxemis - Publications
Home Technology Indications Collaborations Company Publications Contact


Exoxemis’ scientific team members are active contributors to the field’s body of knowledge in MPO technology. more >>


Haloperoxidase Literature

An extensive literature on haloperoxidases supports the broad microbicidal activity of MPO and EPO. more >>


E-mail Inquiries


Are new threats emerging beyond MRSA?
An article appearing recently in The New York Times discusses gram-negative bacteria, such as Acinetobacter baumannii, that are beginning to exhibit antimicrobial resistance in hospital and community settings. Learn more >>

Targeting ‘bad bugs’ without inducing resistance
A prominent voice in the discussion about antimicrobial resistance is the Infectious Disease Society of America (IDSA). IDSA continues to emphasize to policymakers and the public-health community the critical need to develop new treatments to combat drug-resistant organisms.

The society’s landmark 2004 report, “Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates ... A Public Health Crisis Brews,” outlines the growing problem of antimicrobial resistance and the need for a stronger pipeline of antimicrobial drugs to meet current and future public health needs.

In a 2006 update to the report, IDSA names 6 drug-resistant “superbugs” that are most worrisome for healthcare providers: methicillin-resistant Staphylococcus aureus (MRSA); Escherichia coli and Klebsiella species; Acinetobacter baumannii; Aspergillus fungi; vancomycin-resistant Enterococcus faecium (VRE); and Pseudomonas aeruginosa.

Exoxemis’ patented haloperoxidase enzyme technology works to kill these target pathogens, among other organisms of concern, using a unique mechanism of action that is unlikely to induce resistance. Find out more

The most recent update from IDSA about the antimicrobial development pipeline is a 2008 report titled, “Bad Bugs, No Drugs: No ESKAPE!” The report is available here.